Vascular targeting agents enhance chemotherapeutic agent activities in solid tumor therapy.
about
Tumor resistance to vascular disrupting agents: mechanisms, imaging, and solutionsAntitumor effects of combining docetaxel (taxotere) with the antivascular action of ultrasound stimulated microbubblesRoadmap to Clinical Use of Gold Nanoparticles for Radiation Sensitization.A Phase Ib trial of CA4P (combretastatin A-4 phosphate), carboplatin, and paclitaxel in patients with advanced cancer.Antivascular therapy for epithelial ovarian cancer.Targeted therapies in epithelial ovarian cancer.DMXAA causes tumor site-specific vascular disruption in murine non-small cell lung cancer, and like the endogenous non-canonical cyclic dinucleotide STING agonist, 2'3'-cGAMP, induces M2 macrophage repolarizationThe unique characteristics of tumor vasculature and preclinical evidence for its selective disruption by Tumor-Vascular Disrupting Agents.The influence of the combined treatment with Vadimezan (ASA404) and taxol on the growth of U251 glioblastoma xenograftsSupport of a free radical mechanism for enhanced antitumor efficacy of the microtubule disruptor OXi4503.The vascular-ablative agent VEGF(121)/rGel inhibits pulmonary metastases of MDA-MB-231 breast tumors.Design, Synthesis and Cytotoxicity Evaluationof New 1,2-diaryl-4, 5, 6, 7-Tetrahydro-1H-benzo[d] Imidazolesas Tubulin Inhibitors.An in vivo role for Rho kinase activation in the tumour vascular disrupting activity of combretastatin A-4 3-O-phosphate.Potential of DMXAA combination therapy for solid tumors.Activity of the vascular-disrupting agent 5,6-dimethylxanthenone-4-acetic acid against human head and neck carcinoma xenograftsDrugs that target dynamic microtubules: a new molecular perspectiveTumor angiogenesis as a target for dietary cancer preventionEvaluation of tumor ischemia in response to an indole-based vascular disrupting agent using BLI and (19)F MRI.Vascular targeting agents.Targeting the tumor vasculature: a strategy to improve radiation therapy.Characterizing the tumor response to treatment with combretastatin A4 phosphate.Combretastatin A4 phosphate: background and current clinical status.Low Z target switching to increase tumor endothelial cell dose enhancement during gold nanoparticle-aided radiation therapy.Preclinical Activity of the Vascular Disrupting Agent OXi4503 against Head and Neck CancerSequence dependent antitumour efficacy of the vascular disrupting agent ZD6126 in combination with paclitaxel.Temporal aspects of the action of ASA404 (vadimezan; DMXAA).ZD6126 inhibits orthotopic growth and peritoneal carcinomatosis in a mouse model of human gastric cancer.Tumour targeting by microtubule-depolymerizing vascular disrupting agents.Recombinant vascular basement-membrane-derived multifunctional peptide inhibits angiogenesis and growth of hepatocellular carcinoma.Vascular priming enhances chemotherapeutic efficacy against head and neck cancer.Vascular targeted therapies in oncology.Microtubule dynamics as a target in oncology.Dual targeting of tumor vasculature: combining Avastin and vascular disrupting agents (CA4P or OXi4503).Recent advances in tumor vasculature targeting using liposomal drug delivery systems.Tumor vasculature as target for therapeutic intervention.Vascular-disrupting agents in oncology.An update on the clinical development of drugs to disable tumor vasculature.Vascular disrupting activity and the mechanism of action of EHT 6706, a novel anticancer tubulin polymerization inhibitor.Targeted concurrent and sequential delivery of chemotherapeutic and antiangiogenic agents to the brain by using drug-loaded nanofibrous membranes.Antivascular effects of TZT-1027 (Soblidotin) on murine Colon26 adenocarcinoma.
P2860
Q26774355-F7B80025-DF02-4784-B258-EC54CC62226EQ28484485-348B4A1D-860D-46C5-8154-B5E9554E752CQ30366774-1EE12A07-03FD-4E86-B415-537470D9134BQ33389126-EA1C903D-A9D4-4A21-8C24-2A2CF1718F94Q33583598-04820CDD-30B5-4EAB-BFAB-0B3B5F4DD48EQ33606699-4040ED33-517B-48EC-982D-3FE844B6C6B3Q33773787-3F21C08A-71AC-4C18-8707-17FBBF2DA412Q34122191-7FAD26DE-BBFE-46AE-BB29-E7FBD44211F5Q34303312-F4AF0AF9-B2CB-461A-BC95-C9ACF2C9C3FDQ34491366-79EB57FD-8262-44A6-90B2-4F5DB5828D74Q34768492-DB26A7FB-ECEA-4DFF-808C-939D6CDD1AD9Q34777723-3E1A4D8F-F378-445A-BB12-D0219D43DE5BQ34954063-17AFA2A8-BAA5-4887-8643-03DA0E8BDBC0Q34969287-B245F67B-B5DE-4B63-9CAB-D541B7CDE4B6Q35082693-B7D004C8-1601-42BE-99BE-0B98AD88E07CQ35163252-8F227575-4DA1-4B9C-A20A-7DE4C298B129Q35250910-7A2066DF-97D9-4A07-B67C-244667AFA330Q35402062-0E56CFD8-89A5-40D0-8A18-BFCE6556BF47Q35642613-B2FA3C90-5426-4E78-A4F7-0BD8609AEBB8Q35728789-20BFE1CE-AAD2-4411-B781-00662C223B92Q35793182-8DE28490-BFE3-4CA6-88F2-2CAC0814D939Q35871932-096FF2C9-9E7B-4521-A884-A9E33D8F9CC1Q36421581-45AF61F1-A7E0-4BF3-952D-09F3AC4CDE07Q36506995-4FE41D2A-C33F-40BF-9E60-95C748B1BF9AQ36611295-7DAD9925-B1C6-404B-AC65-2AD0D66D61CCQ36641876-91EA1FCF-A287-4A98-94FA-2C01738CBC1FQ36696611-2A8D8E83-314A-44CD-B67F-DC6AADEFF642Q37008845-16932CE5-5854-4420-9032-B0C35E0E40F5Q37157832-4FC11600-04FC-4F7A-B32B-56604782E47AQ37169566-0B12E629-BEDA-4FA1-A6FC-13C5F390B9A6Q37254370-8F47B15C-801B-49DB-AD7D-87ACDBBDEB17Q37360708-D5C600C8-C6DE-44EA-A955-53252BB175B3Q37458557-A9A1F005-B6E9-4AC7-B77A-220B900D028DQ37603355-A196BA4B-AE19-4008-9C56-CB2144989707Q37800110-E72DFE7D-5403-4FEE-BA00-39521B061931Q38073812-AD6B7959-2D79-454F-9EB8-E7E299EDDAE4Q38088732-B3B463C7-2503-4D06-8891-97DD2F7038B3Q38322817-4922B542-36D0-4C39-8D75-AEC1A140F50EQ38938545-6DE2BCE1-0424-4357-A8E4-721563FA0ACCQ40227957-4B7A02FE-FD41-468E-8C1E-FDA4B21D069E
P2860
Vascular targeting agents enhance chemotherapeutic agent activities in solid tumor therapy.
description
2002 nî lūn-bûn
@nan
2002年の論文
@ja
2002年学术文章
@wuu
2002年学术文章
@zh-cn
2002年学术文章
@zh-hans
2002年学术文章
@zh-my
2002年学术文章
@zh-sg
2002年學術文章
@yue
2002年學術文章
@zh
2002年學術文章
@zh-hant
name
Vascular targeting agents enha ...... vities in solid tumor therapy.
@en
Vascular targeting agents enha ...... vities in solid tumor therapy.
@nl
type
label
Vascular targeting agents enha ...... vities in solid tumor therapy.
@en
Vascular targeting agents enha ...... vities in solid tumor therapy.
@nl
prefLabel
Vascular targeting agents enha ...... vities in solid tumor therapy.
@en
Vascular targeting agents enha ...... vities in solid tumor therapy.
@nl
P2093
P2860
P356
P1476
Vascular targeting agents enha ...... vities in solid tumor therapy.
@en
P2093
Amyn M Rojiani
Dietmar W Siemann
Emma Mercer
Sharon Lepler
P2860
P356
10.1002/IJC.10316
P577
2002-05-01T00:00:00Z